Which has preferable earnings and valuation, RIGL or GRAL?

Rigel Pharmaceuticals has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rigel Pharmaceuticals $294.28M 2.97 $367.02M $16.32 2.89 GRAIL $147.17M 23.14 -$408.35M -$9.75 N/A

Does the media favor RIGL or GRAL?

In the previous week, GRAIL had 9 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 11 mentions for GRAIL and 2 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.94 beat GRAIL's score of 0.94 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive GRAIL 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IDYA or RIGL?

In the previous week, IDEAYA Biosciences had 11 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 13 mentions for IDEAYA Biosciences and 2 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.94 beat IDEAYA Biosciences' score of 0.61 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend RIGL or GMTX?

Rigel Pharmaceuticals presently has a consensus target price of $59.00, suggesting a potential upside of 24.89%. Given Rigel Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Rigel Pharmaceuticals is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rigel Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Rigel Pharmaceuticals (RIGL) Competitors

$47.24 -0.04 (-0.08%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$47.32 +0.07 (+0.16%)

As of 09/11/2026 07:30 PM Eastern

Compare

RIGL vs. GRAL, DNLI, ABCL, IDYA, and GMTX

Should you buy Rigel Pharmaceuticals stock or one of its competitors? Rigel Pharmaceuticals's main competitors and comparable companies include GRAIL (GRAL), Denali Therapeutics (DNLI), AbCellera Biologics (ABCL), IDEAYA Biosciences (IDYA), and Gemini Therapeutics (GMTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rigel Pharmaceuticals compare to GRAIL?

Rigel Pharmaceuticals (NASDAQ:RIGL) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Rigel Pharmaceuticals presently has a consensus price target of $59.00, indicating a potential upside of 24.89%. GRAIL has a consensus price target of $71.11, indicating a potential downside of 6.72%. Given Rigel Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Rigel Pharmaceuticals is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 1.8% of GRAIL shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Rigel Pharmaceuticals has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, GRAIL has a beta of 3.25, meaning that its share price is 225% more volatile than the broader market.

Rigel Pharmaceuticals has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.97	$367.02M	$16.32	2.89
GRAIL	$147.17M	23.14	-$408.35M	-$9.75	N/A

Rigel Pharmaceuticals has a net margin of 116.30% compared to GRAIL's net margin of -236.95%. Rigel Pharmaceuticals' return on equity of 22.95% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	116.30%	22.95%	17.19%
GRAIL	-236.95%	-15.88%	-14.02%

In the previous week, GRAIL had 9 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 11 mentions for GRAIL and 2 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.94 beat GRAIL's score of 0.94 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GRAIL	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rigel Pharmaceuticals beats GRAIL on 12 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Rigel Pharmaceuticals has a net margin of 116.30% compared to Denali Therapeutics' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 22.95% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 9.7% of Denali Therapeutics shares are owned by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Rigel Pharmaceuticals had 1 more articles in the media than Denali Therapeutics. MarketBeat recorded 2 mentions for Rigel Pharmaceuticals and 1 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.84 beat Rigel Pharmaceuticals' score of 0.94 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Denali Therapeutics	Very Positive
Rigel Pharmaceuticals	Positive

Denali Therapeutics presently has a consensus price target of $35.85, indicating a potential upside of 69.97%. Rigel Pharmaceuticals has a consensus price target of $59.00, indicating a potential upside of 24.89%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Denali Therapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Rigel Pharmaceuticals has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	10.20	-$512.54M	-$2.84	N/A
Rigel Pharmaceuticals	$294.28M	2.97	$367.02M	$16.32	2.89

Denali Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Summary

Rigel Pharmaceuticals beats Denali Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to AbCellera Biologics?

Rigel Pharmaceuticals (NASDAQ:RIGL) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Rigel Pharmaceuticals has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.97	$367.02M	$16.32	2.89
AbCellera Biologics	$75.13M	44.44	-$146.41M	-$0.54	N/A

Rigel Pharmaceuticals has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

Rigel Pharmaceuticals presently has a consensus target price of $59.00, indicating a potential upside of 24.89%. AbCellera Biologics has a consensus target price of $12.83, indicating a potential upside of 17.85%. Given Rigel Pharmaceuticals' higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Rigel Pharmaceuticals has a net margin of 116.30% compared to AbCellera Biologics' net margin of -248.83%. Rigel Pharmaceuticals' return on equity of 22.95% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	116.30%	22.95%	17.19%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

In the previous week, Rigel Pharmaceuticals had 1 more articles in the media than AbCellera Biologics. MarketBeat recorded 2 mentions for Rigel Pharmaceuticals and 1 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.45 beat Rigel Pharmaceuticals' score of 0.94 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Rigel Pharmaceuticals	Positive
AbCellera Biologics	Positive

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Rigel Pharmaceuticals beats AbCellera Biologics on 10 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rigel Pharmaceuticals has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	15.10	-$113.70M	-$1.94	N/A
Rigel Pharmaceuticals	$294.28M	2.97	$367.02M	$16.32	2.89

Rigel Pharmaceuticals has a net margin of 116.30% compared to IDEAYA Biosciences' net margin of -75.93%. Rigel Pharmaceuticals' return on equity of 22.95% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

In the previous week, IDEAYA Biosciences had 11 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 13 mentions for IDEAYA Biosciences and 2 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.94 beat IDEAYA Biosciences' score of 0.61 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEAYA Biosciences currently has a consensus price target of $52.69, indicating a potential upside of 40.18%. Rigel Pharmaceuticals has a consensus price target of $59.00, indicating a potential upside of 24.89%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe IDEAYA Biosciences is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

IDEAYA Biosciences has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Summary

Rigel Pharmaceuticals beats IDEAYA Biosciences on 10 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Gemini Therapeutics?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than Gemini Therapeutics. MarketBeat recorded 2 mentions for Rigel Pharmaceuticals and 0 mentions for Gemini Therapeutics. Rigel Pharmaceuticals' average media sentiment score of 0.94 beat Gemini Therapeutics' score of 0.00 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Rigel Pharmaceuticals	Positive
Gemini Therapeutics	Neutral

Rigel Pharmaceuticals has a net margin of 116.30% compared to Gemini Therapeutics' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 22.95% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	116.30%	22.95%	17.19%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Rigel Pharmaceuticals has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market.

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Rigel Pharmaceuticals has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.97	$367.02M	$16.32	2.89
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Rigel Pharmaceuticals presently has a consensus target price of $59.00, suggesting a potential upside of 24.89%. Given Rigel Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Rigel Pharmaceuticals is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Rigel Pharmaceuticals beats Gemini Therapeutics on 13 of the 15 factors compared between the two stocks.

Get Rigel Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RIGL vs. The Competition

Export

Metric	Rigel Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$874.04M	$3.86B	$7.16B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	2.89	8.41	214.39	20.85
Price / Sales	2.97	1,378.88	633.80	90.72
Price / Cash	7.01	43.64	28.42	34.96
Price / Book	2.19	15.12	10.33	6.21
Net Income	$367.02M	-$22.86M	$3.50B	$358.54M
7 Day Performance	-2.94%	-4.34%	-3.32%	-2.35%
1 Month Performance	15.81%	0.54%	-0.53%	-3.23%
1 Year Performance	24.45%	40.74%	23.51%	8.79%

Rigel Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RIGL Rigel Pharmaceuticals	4.4701 of 5 stars	$47.24 -0.1%	$59.00 +24.9%	+24.4%	$874.04M	$294.28M	2.89	174	Analyst Upgrade
GRAL GRAIL	0.559 of 5 stars	$80.34 flat	$67.78 -15.6%	+100.4%	$3.59B	$147.17M	N/A	1,360	News Coverage Analyst Upgrade
DNLI Denali Therapeutics	3.749 of 5 stars	$22.28 flat	$35.85 +60.9%	+48.6%	$3.56B	$330.53M	N/A	430	Positive News
ABCL AbCellera Biologics	2.395 of 5 stars	$11.43 flat	$12.83 +12.3%	+143.6%	$3.50B	$75.13M	N/A	500	Positive News
IDYA IDEAYA Biosciences	3.1063 of 5 stars	$39.86 flat	$51.93 +30.3%	+52.7%	$3.50B	$218.71M	N/A	80	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RIGL) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rigel Pharmaceuticals (RIGL) Competitors

RIGL vs. GRAL, DNLI, ABCL, IDYA, and GMTX

How does Rigel Pharmaceuticals compare to GRAIL?

Summary

How does Rigel Pharmaceuticals compare to Denali Therapeutics?

Summary

How does Rigel Pharmaceuticals compare to AbCellera Biologics?

Summary

How does Rigel Pharmaceuticals compare to IDEAYA Biosciences?

Summary

How does Rigel Pharmaceuticals compare to Gemini Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RIGL vs. The Competition

Rigel Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rigel Pharmaceuticals (RIGL) Competitors

RIGL vs. GRAL, DNLI, ABCL, IDYA, and GMTX

How does Rigel Pharmaceuticals compare to GRAIL?

Do analysts rate RIGL or GRAL?

Do insiders & institutionals have more ownership in RIGL or GRAL?

Which has more risk & volatility, RIGL or GRAL?

Which has preferable earnings and valuation, RIGL or GRAL?

Is RIGL or GRAL more profitable?

Does the media favor RIGL or GRAL?

Summary

How does Rigel Pharmaceuticals compare to Denali Therapeutics?

Is DNLI or RIGL more profitable?

Do institutionals & insiders believe in DNLI or RIGL?

Does the media prefer DNLI or RIGL?

Do analysts prefer DNLI or RIGL?

Which has preferable valuation & earnings, DNLI or RIGL?

Which has more volatility & risk, DNLI or RIGL?

Summary

How does Rigel Pharmaceuticals compare to AbCellera Biologics?

Which has better valuation & earnings, RIGL or ABCL?

Which has more risk & volatility, RIGL or ABCL?

Do analysts recommend RIGL or ABCL?

Is RIGL or ABCL more profitable?

Does the media favor RIGL or ABCL?

Do institutionals and insiders believe in RIGL or ABCL?

Summary

How does Rigel Pharmaceuticals compare to IDEAYA Biosciences?

Do insiders and institutionals have more ownership in IDYA or RIGL?

Which has preferable earnings & valuation, IDYA or RIGL?

Is IDYA or RIGL more profitable?

Does the media refer more to IDYA or RIGL?

Do analysts prefer IDYA or RIGL?

Which has more volatility and risk, IDYA or RIGL?

Summary

How does Rigel Pharmaceuticals compare to Gemini Therapeutics?

Does the media favor RIGL or GMTX?

Is RIGL or GMTX more profitable?

Which has more risk and volatility, RIGL or GMTX?

Do institutionals & insiders hold more shares of RIGL or GMTX?

Which has preferable earnings & valuation, RIGL or GMTX?

Do analysts recommend RIGL or GMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RIGL vs. The Competition

Rigel Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools